Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients With Moderate-to-Severe Atopic Dermatitis. J of Skin 2020, 4 (6), s98. https://doi.org/10.25251/skin.4.supp.98.